Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glutamate receptor, metabotropic 2 | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | sodium bile acid cotransporter | 0.1506 | 1 | 1 |
Echinococcus multilocularis | metabotropic glutamate receptor 5 | 0.0075 | 0.0308 | 0.0165 |
Onchocerca volvulus | 0.1506 | 1 | 0.5 | |
Schistosoma mansoni | sodium-bile acid cotransporter related | 0.0611 | 0.3935 | 0.3935 |
Echinococcus granulosus | sodium bile acid cotransporter | 0.1506 | 1 | 1 |
Brugia malayi | Metabotropic glutamate receptor precursor. | 0.0061 | 0.0212 | 0.0212 |
Schistosoma mansoni | metabotropic glutamate receptor | 0.0051 | 0.0145 | 0.0145 |
Echinococcus granulosus | sodium bile acid cotransporter | 0.1506 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0075 | 0.0308 | 0.0098 |
Schistosoma mansoni | sodium-bile acid cotransporter related | 0.1506 | 1 | 1 |
Schistosoma mansoni | metabotropic glutamate receptor 2 3 (mglur group 2) | 0.0069 | 0.0269 | 0.0269 |
Loa Loa (eye worm) | hypothetical protein | 0.1506 | 1 | 1 |
Brugia malayi | metabotropic glutamate receptor subtype 5a (mGluR5a), putative | 0.0055 | 0.0173 | 0.0173 |
Schistosoma mansoni | sodium-bile acid cotransporter | 0.0896 | 0.5863 | 0.5863 |
Echinococcus granulosus | sodium bile acid cotransporter | 0.1506 | 1 | 1 |
Echinococcus multilocularis | sodium bile acid cotransporter | 0.1506 | 1 | 1 |
Echinococcus multilocularis | sodium bile acid cotransporter | 0.1506 | 1 | 1 |
Echinococcus granulosus | metabotropic glutamate receptor 5 | 0.0075 | 0.0308 | 0.0165 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Brain/Plasma (ADMET) | 0 | Ratio of brain to plasma levels was determined upon administration at 20 mpk intraperitoneally after 2 h; Not determined | ChEMBL. | 15501058 |
Cl (ADMET) | = 75 ml min-1 kg-1 | Total clearance of the compound in rat plasma upon administration at 2 mpk iv or 10 mpk po | ChEMBL. | 15501058 |
Concentration in Brain (ADMET) | 0 nM | Compound level in rat brain was determined upon administration at 2 mpk iv or 10 mpk po; Not determined | ChEMBL. | 15501058 |
EC50 (functional) | = 558 nM | Binding affinity towards human metabotropic glutamate receptor 2 determined by [35S]-GTP gama S binding assay | ChEMBL. | 15501058 |
EC50 (functional) | = 558 nM | Binding affinity towards human metabotropic glutamate receptor 2 determined by [35S]-GTP gama S binding assay | ChEMBL. | 15501058 |
F (ADMET) | = 0 % | Bioavailability in rat (dose 2 mg/kg i.v. and 10 mg/kg p.o.) | ChEMBL. | 15501058 |
Potentiation (binding) | = 88 % | Potentiation as percent of maximum glutamate response at 1 mM | ChEMBL. | 15501058 |
Potentiation (binding) | = 88 % | Potentiation as percent of maximum glutamate response at 1 mM | ChEMBL. | 15501058 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.